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Abstract
Background Advanced heart failure (HF) is associated with
high morbidity and mortality; it represents a major burden
for the health system. Episodes of acute decompensation
requiring frequent and prolonged hospitalizations account
for most HF-related expenditure. Inotropic drugs are fre-
quently used during hospitalization, but rarely in out-
patients. The LAICA clinical trial aims to evaluate the effec-
tiveness and safety of monthly levosimendan infusion in
patients with advanced HF to reduce the incidence of hospi-
tal admissions for acute HF decompensation.
Methods The LAICA study is a multicenter, prospective,
randomized, double-blind, placebo-controlled, parallel group
trial. It aims to recruit 213 out-patients, randomized to receive
either a 24-h infusion of levosimendan at 0.1 μg/kg/min dose,
without a loading dose, every 30 days, or placebo.
Results The main objective is to assess the incidence of
admission for acute HF worsening during 12 months. Sec-
ondarily, the trial will assess the effect of intermittent
levosimendan on other variables, including the time in days
from randomization to first admission for acute HF worsen-
ing, mortality and serious adverse events.
Conclusions The LAICA trial results could allow confirma-
tion of the usefulness of intermittent levosimendan infusion
in reducing the rate of hospitalization for HF worsening in
advanced HF outpatients.
A complete list of LAICA Investigators is shown in Appendix 1.
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Introduction
Advanced heart failure (HF) is a health problem of increas-
ing magnitude [1–3] despite the significant advances of
recent decades [4]. It is characterized by repeated episodes
of decompensation that cause frequent and prolonged hospi-
talizations [5]. As a consequence, the quality of life of these
patients is severely compromised and the economic burden
of healthcare is high [6, 7]. Some patients may benefit from
therapeutic measures with known impact on survival and
quality of life, such as the implantation of circulatory assist
devices and heart transplantation [8]. However, in many
cases, such measures may be delayed due to shortage of
donor organs, or contraindicated due to host factors such as
advanced age and co-morbidity [9, 10].
In recent years a new drug, levosimendan, has emerged in
the therapeutic management of HF. It is a calcium-sensitizing
agent, which exerts a combined positive inotropic and vaso-
dilator effect [11]. There is extensive scientific evidence on
the effectiveness and utility of levosimendan in treating
patients with acutely decompensated HF [12–15]. It is there-
fore commonly used in many hospitals around the world.
However, there are no efficacy and safety data to support the
use of intermittent levosimendan for the management of
outpatients with advanced HF.
The LAICA study (ClinicalTrials.gov Identifier:
NCT00988806/Number EudraCT: 2009-011441-11) is an
independent multicenter clinical trial designed to evaluate
the efficacy and safety of intermittent administration of
levosimendan in continuous 24 h intravenous infusion as a
treatment strategy to reduce the incidence of hospital admis-
sion for acutely decompensated HF, at 12 months follow-up,
in patients with advanced HF.
Methods
Study Design, Duration, Levosimendan Administration
and Treatments Allowed
The LAICA study is a multicenter, prospective, randomized,
double-blind, placebo-controlled, parallel group trial. Can-
didate participants are patients with advanced HF [5], of any
aetiology, with at least one episode of acute decompensation
requiring admission within the last 6 months, and clinically
stable at the time of inclusion in the study (see Table 1 for
inclusion and exclusion criteria). Study duration is 12months
of treatment and 12 months of follow up. All patients receive
standard treatment for HF, at the discretion of the physician
responsible in each case, in accordance with current recom-
mendations for the management of chronic heart failure [4]
and may be carriers of an implantable cardioverter defibril-
lator or cardiac resynchronization therapy device. Patients
are randomly assigned, in double-blind manner, to receive an
infusion of levosimendan at 0.1 μg/kg/min, without a load-
ing dose (Group I), or placebo of the same colour, at the same
dosis (Group II), during 24 h, once every 30 days. The dose
is established on the basis of previous studies [14, 15],
researcher experience and the usual practice in many centres.
The absence of a loading dose is for safety reasons (to avoid
the risk of episodes of hypotension). The infusion rate may be
reduced to 0.05 μg/kg/min or suspended, according to the
patient’s response to the drug (hypotension or tachycardia),
Table 1 Inclusion and exclusion criteria
Inclusion Criteria
Age>18 years old
Symptoms of heart failure such as dysnea or weakness on minimal
physical activity or at rest (NYHA III–IV functional class)
Congestive signs (jugular venous distension, liver distension, lung
crepitations or rales, peripheral edema) o low-output signs at rest
Evidence of severe heart dysfunction defined as one of the following :
• Ejection fraction less than 30 %
• Diastolic dysfunction>grade III
• Pulmonary capillary wedge pressure>16 mmHg and/or central
venous pressure>12 mmHg at pulmonary artery catheterization
• NTproBNP levels>3,000 ng/mL, when non-cardiac conditions
are ruled out
Severe impairment of functional capacity evidenced by one of the
following:
• Six-minutes walking test in women and/or patients>75 years :
< 300 m response
• Oxygen consumption during cardiopulmonary treadmill test :
< 12–14 mL/kg/min response




Allergy or hypersensitivity to levosimendan or any of the components




Women of childbearing age
Cardiac conditions associated with cardiac filling or output obstruction
Systolic tension<90 mmHg
Heart rate>120 bpm or history of torsade de pointes
Treatment with vasoactive amines or phosphodiesterase inhibitors in
the 2 weeks before randomization
Any associated disease with poor prognosis and/or reduced survival time
Inability to give informed consent
Concomitant participation in other studies
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in which case it will be recorded as a serious adverse
event. Infusion of the drug will take place in a medical
setting, under clinical supervision with electrocardiogra-
phy and non-invasive hemodynamic monitoring. Clinical
status of each participant will be evaluated at 15 days
of infusion. If the patient is not found in a state of
adequate compensation (defined as subjective improve-
ment of HF symptoms and/or improvement by at least
one NYHA functional class, and/or objective disappear-
ance of signs of systemic venous congestion, pulmonary
congestion and/or objective improvement in signs of
peripheral perfusion) or if the clinical status worsens
before the 30-day deadline for the next infusion, then
the infusion timetable will be shortened to every 15 days
with clinical assessments at 7 days. In cases of persis-
tent decompensation after two consecutive infusions ev-
ery 15 days, the randomization code will be disclosed
and the patient receive the medical treatment deemed
most appropriate by the attending physician, including heart
transplantation when indicated. A complete summary of the
protocol is depicted in Fig. 1.
Randomization, Infusion Masking Procedure and Ethical
Considerations
Patients will be centrally randomized using a random num-
ber generator. Patient identification and drug/placebo numer-
ic codes will be safeguarded in the Pharmacy Department,
University Hospital of the Canary Islands. The infusion
masking will only be removed in cases of a serious adverse
event or when the primary endpoint of the trial is attained.
The study drug and placebo will be presented as a concen-
trate in 5 ml vials of identical appearance.
The study has been approved by local clinical research ethics
committees of each participating center and by the health
authorities (Spanish Agency ofMedicines and Health Products,
Ministry of Health). It will be conducted in accordance with the
standards of Good Clinical Practice for trials with medical
products in the European Community (http://www.ec.europa.
eu/health/documents/eudralex/vol-10/index_en.htm) and the
Declaration of Helsinki concerning medical research in human
subjects [16]. An independent ad hoc clinical events committee,
blinded to the treatment received, will supervise the course and
Fig. 1 Summary of study design protocol
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safety of the study. It will receive reports on all events relating
to the primary objective, secondary objectives and adverse
reactions that may occur during implementation. An interim
analysis will be performed to evaluate the efficacy and safety of
the study when the first 100 patients are recruited.
Main and Secondary Objectives of the Study
The primary endpoint of the trial is to determine the inci-
dence of combined overall mortality and admission for acute
HF decompensation or worsening. Clinical worsening or
acutely decompensated heart failure is defined as admission
to the emergency department or a hospital ward during more
than 12 h due to worsening of symptoms and signs of HF.
The effect of study drug administration on other secondary
end-points will also be evaluated [Table 2].
The end-points of the study will be evaluated at patient
visits between each administration of the study drug, based on
history, physical signs, laboratory tests (blood count, renal
function, ions and NTproBNP), echocardiography, functional
assessment by treadmill test with measurement of myocardial
oxygen consumption or a 6-min walking test, and evaluation
of quality of life using the validated Spanish version of the
Kansas City Cardiomyopathy Questionnaire [17] at baseline,
and at 3,6 and 12 months of inclusion in the study.
Sub-Study on Renal Function Previous studies suggest that
levosimendan treatment has a beneficial effect of on renal
function [14]. The objective of this sub-study is to confirm
any such effect on renal function in patients with advanced
HF. Glomerular filtration rate will be estimated using the
MDRD formula [18] after randomization, at 30 days, 3, 6
and 12 months of inclusion in the study. Additionally,
cystatin C levels will be measured at baseline, and at 6 and
12 months of inclusion in the study.
Sub-Study on Cost-Effectiveness The objective of this sub-
study is to assess the impact in terms of cost-efficacy of
repeated doses of levosimendan in patients with advanced
HF. As markers of cost-effectiveness we will use the number
of hospitalizations, number of days spent in the intensive
care unit and/or hospital ward, and the number of visits to
primary care. The impact on quality of life and health status
of the participants will be assessed using the KCCQ ques-
tionnaire at baseline and at each follow-up visit.
Sample Size Rationale, Data Collection and Statistical
Analysis In calculating the study sample size we used data
from a previous study by W. Mullens et al. [19]: in a cohort
of 513 advanced HF patients on standard treatment, the 1-
year incidence of hospital admission for HF worsening was
38 %. Thus, for our study to have a power of 80 % and an
alpha risk of 0.05 (one-tailed contrast) we need 213 patients
(163 patients to receive levosimendan treatment and 50
patients placebo), assuming a final result of 18 % reduction
in the incidence of the primary endpoint of the study.
All patient data are to be collected centrally on an electronic
data spreadsheet using a telematic application with predefined
ranges, controls to prevent double entry and warnings about
erroneous data entry. Patient identity will be encrypted to
protect the safety and confidentiality of their data. Patients
who during the study period are eligible but not randomized
for any reason will be included in a simplified register and the
reason for their non-inclusion will be specified, but they will
be subject to follow-up at 30 days and 12 months.
Statistical analysis will be performed according to the
intention-to-treat (ITT) principle. There will be a descriptive
analysis of all variables collected (i.e. variables related to
efficacy and safety, and all variables that may be considered
as related to them) for both treatment groups. Variables
will be compared between groups according to original
patient randomization to a group (in accord with the
ITT principle). Statistical analysis will be performed by
an independent group of experts in biostatistics and research
methodology. For missing data (partial and complete), statis-
tical imputation with “last observation carried forward” will
be used.
Discussion
The management of HF accounts for 2 % of health expendi-
ture in industrialized countries, and 70 % of that is due to
frequent and prolonged hospitalizations for acutely
decompensated HF [6]. Strategies to reduce such hospitali-
zations could help reduce the burden of HF care. The aim of
the LAICA study is to determine whether the intermittent
administration of levosimendan by intravenous infusion dur-
ing 24 h once every 30 days is safe and effective in reducing
Table 2 Primary and secondary end-points
Primary end-point
Combined overall mortality and admission for HF decompensation
or worsening
Secondary end-points
Time in days from randomization to first hospitalization for ADHF
Overall mortality at 1,6 and 12 months
Cardiac and non-cardiac mortality at 1,6,12 months
Cumulative incidence of mortality and hospitalization rate for ADHF
Incidence of Major Adverse Cardiac Events (MACE) such as sudden
death, myocardial ischemia, acute myocardial infarction
Time in days from randomization to any MACE
Changes in NYHA functional class from randomization to
1,6,12 months
NTproBNP changes before and after treatment
Quality of Life assessment at 1,6,12 months using KCCQ
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the incidence of admission for acute decompensation in
patients with advanced HF.
The administration of inotropic drugs, by continuous or
intermittent infusion, is frequently used in hospitalized pa-
tients with advanced HF in order to improve quality of life
and survival or as a bridge to transplantation [4, 20]. Al-
though inotropes can immediately improve clinical status
and hemodynamics, they may trigger and accelerate patho-
physiological mechanisms that lead to increased myocardial
damage. Numerous studies have shown that this method of
administration has short-to-long term negative effects, includ-
ing increased myocardial oxygen requirements, cardiotoxicity
and pro-arrhythmogenic effects which significantly limit their
usefulness as therapeutic agents [21, 22].
Levosimendan, a calcium sensitizing agent, has inotropic
and vasodilator effects exerted by a dual mechanism of action:
1) it increases the calcium sensitivity of troponin C, without
increasing the release of calcium into the cytosol or modifying
intracellular cyclic AMP levels, and 2) it activates K+-ATPase-
dependent channels and blocks the release of endothelin-1. This
dual mechanism of action leads to improved myocardial con-
tractility without either significant changes in oxygen require-
ments or pro-arrhythmic effects [11].
Different studies have demonstrated the effectiveness of
levosimendan in treating acute HF decompensation from the
clinical, hemodynamic, and even prognostic standpoint, com-
pared with other treatment arms [12–15]. However, others
have subsequently questioned the benefits for long-term prog-
nosis of these patients [23, 24]. This disparity of results has
been attributed to methodological differences [25].
Preliminary studies, all with small sample sizes, have
examined the effects of administering levosimendan in re-
peated doses for the treatment of HF. In 36 patients with
advanced HF, Nanas et al. [26] studied the efficacy and safety
of biweekly levosimendan associated with dobutamine com-
pared with dobutamine alone. Patients receiving levosimendan
survived longer.
Parisis et al. [27], in a randomized placebo-controlled study
involving 25 patients with advanced HF, studied the effect of
levosimendan infusion during 24 h every 3 weeks on cardiac
function, geometry and levels of troponin T, NT-proBNP,
high sensitivity C-reactive protein and interleukin-6. Repeated
levosimendan infusions significantly improved geometry and
cardiac function, and positively modulated neuro-hormonal
activation and inflammatory response in patients with ad-
vanced HF without increasing myocardial damage.
Mavrogeni et al. [28], in 50 patients with advanced HF,
prospectively evaluated the clinical effect of intermittent
monthly infusion of levosimendan during 24 h, compared to
controls receiving standard care, for 6 months. The results
showed significant symptom improvement in those receiving
intermittent levosimendan, together with an increase in left
ventricular systolic function.
Parle et al. [29], in a prospective observational study, studied
the effectiveness of repeated infusions of levosimendan in 45
patients with advanced HF. They showed that levosimendan
can be administered repeatedly, was well tolerated, with im-
provements in functional class and BNP levels after drug
infusions.
Two current multicenter studies are aimed at assessing the
efficacy and safety of intermittent levosimendan administra-
tion in patients with advanced HF. Altenberger et al. [30] in a
prospective, randomized, double-blind, placebo-controlled,
parallel group trial (the LevoRep study, ClinicalTrials.gov
Identifier: NCT01065194) evaluated the efficacy and safety
of levosimendan infusion every 2 weeks during 6 h in 120
outpatients with advanced HF. This study failed to show
significant improvements in its primary objectives: to assess
changes in functional capacity and quality of life at the end of
the 24-week study period. However, the study meets its sec-
ondary end-points and showed that ambulatory levosimendan
was safe and improves event-free survival by 50% in the short
term (8 weeks) and long term (24 weeks) from randomization,
compared with placebo. These authors agree that studies with
more patients and higher dosing or higher repetition frequen-
cies of levosimendan in an outpatient setting could show
positive results for the primary endpoints [31].
The currently ongoing LION-HEART study (Clinical
Trials.gov Identifier: NCT01536132), using a levosimendan
administration regimen similar to that of the LevoRep study,
aims to determine its efficacy and safety in 70 outpatients with
advanced HF, compared with placebo, where the main out-
come variable is the change in BNP levels from baseline to the
end of a 3-month treatment period. Secondary objectives
include the assessment of hospitalizations and mortality at
12 months follow up.
The design of our study differs substantially from
these two studies in terms of the form and duration of
drug administration, and the primary objective. However, we
share the same intention of evaluating the efficacy and safety
of intermittent levosimendan in patients with advanced
HF. Results, if positive, may lead to recommendations
based on scientific evidence in support of the strategy
of repeated intermittent administration of levosimendan
as an additional therapeutic step in the treatment of
patients with advanced HF.
Lastly, the presence of renal function impairment or wors-
ening complicates the management of patients with ad-
vanced HF and is an independent predictor of adverse out-
come [32]. In the LIDO study, a significant reduction in
serum creatinine levels was observed in levosimendan-
treated patients [14]. In addition, other clinical findings
suggest that levosimendan treatment has a beneficial
effect on renal function [32, 33]. The renal sub-study
will allow us to detect this effect in patients with
advanced HF.
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Conclusions
The LAICA study aims to assess the efficacy and safety of
intermittent levosimendan administration as an additional
therapeutic measure in patients with advanced HF, and to
test the hypothesis that its use in outpatients could reduce the
rate of admissions for acutely decompensated HF. If this is
confirmed, it could have important implications for quality
of life and healthcare costs associated with managing pa-
tients with advanced HF.
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